Literature
Abou-Mohamed, G. A., Huang, J., Oldham, C. D., Taylor, T. A., Jin, L., Caldwell, R. B., … Caldwell, R. W. (2000). Vascular and Endothelial Actions of Inhibitors of Substance P Amidation. J. Cardiovascular Pharmacol, 35 , 871-880.
Ali, A., Burns, T. J., Lucrezi, J. D., May, S. W., Green, G. R., & Matesic, D. F. (2015). Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties. Invest.New Drugs, 33 , 827-834.
Andrews, M. D., O’Callaghan, K. A., & Vederas, J. C. (1997). Synthesis of Tripeptide Inhibitors of Peptidylglycine α-Amidating Monooxygenase (PAM) Containing D- and L-Styrylglycine. Tetrahedron, 52 , 8295-8306.
Bäck, N., Kanerva, K., Vishwanatha, K. S., Yanik, A., Ikonen, E., Mains, R. E., & Eipper, B. A. (2017). The endocytic pathways of a secretory granule membrane protein in HEK293 cells: PAM and EGF traverse a dynamic multivesicular body network together. Eur.J.Cell.Biol., 86 , 407-417.
Bäck, N., Luxmi, R., Powers, K. G., Mains, R. E., & Eipper, B. A. (2020). Peptidylglycine α-Amidating Monooxygenase Is Required for Atrial Secretory Granule Formation. Proc Natl Acad Sci U S A, 117 , 17820-17831.
Bäck, N., Mains, R. E., & Eipper, B. A. (2021). Organism and Cell Type Specific Uses of Peptidylglycine α-Amidating Monooxygenase (PAM).